Cetuximab for resectable colorectal liver metastasis: New EPOC trial

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages

  Hasegawa, Kiyoshi ^a   Oba, Masaru ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COLORECTAL LIVER METASTASIS; EXON; HUMAN; LETTER; MORTALITY; ONCOGENE K RAS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; WILD TYPE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84903447999     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70216-5     Document Type: Letter

References (1)

1. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014, 15:601-611.